成年重症哮喘患者的疾病负担和治疗模式:基于中国理赔数据的真实世界研究

Ke Zhang, Xiaoning He, Jing Wu
{"title":"成年重症哮喘患者的疾病负担和治疗模式:基于中国理赔数据的真实世界研究","authors":"Ke Zhang, Xiaoning He, Jing Wu","doi":"10.54844/hd.2024.0011","DOIUrl":null,"url":null,"abstract":"Objective: To assess the treatment pattern and disease burden in adults with severe asthma in China. \nMethods: This retrospective, observational, cohort study with one-year follow-up was conducted using a healthcare claims \ndatabase spanning 2018 through 2020, from Tianjin, China. Patients diagnosed with asthma, who had ≥2 prescriptions of \nmedium-to-high dose of inhaled corticosteroids (ICS) along with additional controllers, were identified to represent severe \nasthma population in China. Patients were categorized as controlled, sub-optimally controlled , and uncontrolled by the times \nof burst systemic corticosteroids, short-acting β2-agonist (SABA) and hospitalization. Medication use, asthma exacerbations, \nand related costs in the follow-up period were also reported. \nResults: 2,418 patients with severe asthma were included, with an average age of 56.15 years, male 55.62%. 93.51% of \npatients used inhaled corticosteroid/long-acting β2 (ICS/LABA). 10.75% of patients used oral corticosteroids (OCS) (6.13%, \n23.83% and 33.96% in controlled, sub-optimally controlled and uncontrolled group, respectively). For patients with OCS, \nthe average duration of OCS was 82.73 days (53.35, 102.27 and 111.21 days in three groups, respectively). 10.67% of \npatients experienced ≥ 1 exacerbation and 3.93% experienced ≥ 2 exacerbations (1.73%,1.68% and 26.89% in three groups, \nrespectively). The average frequency of annual exacerbations was 0.21 (0.09, 0.26 and 1.31 in three groups, respectively). The \naverage cost for per exacerbation was ¥1441.83 (¥293.69, ¥550.86 and ¥2366.86 in three groups respectively). The average \nasthma-related annual cost was ¥2846.08, of which medication costs exceeded 90% (¥2105.70, ¥3559.35 and ¥8506.83 in \nthree groups, respectively). \nConclusion: This study shows that ICS/LABA is widely used in patients with severe asthma, and OCS is more used in patients \nwith uncontrolled asthma. Worse asthma control is associated with more frequent and severe asthma attack and higher medical \ncost, which reveals the necessity of effective management and treatment to improve the asthma control. \nKey words: severe asthma, control level, treatment pattern, disease burden, real-world study","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"59 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Disease burden and treatment patterns in adult patients with severe asthma: A real-world study based on claims data from China\",\"authors\":\"Ke Zhang, Xiaoning He, Jing Wu\",\"doi\":\"10.54844/hd.2024.0011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To assess the treatment pattern and disease burden in adults with severe asthma in China. \\nMethods: This retrospective, observational, cohort study with one-year follow-up was conducted using a healthcare claims \\ndatabase spanning 2018 through 2020, from Tianjin, China. Patients diagnosed with asthma, who had ≥2 prescriptions of \\nmedium-to-high dose of inhaled corticosteroids (ICS) along with additional controllers, were identified to represent severe \\nasthma population in China. Patients were categorized as controlled, sub-optimally controlled , and uncontrolled by the times \\nof burst systemic corticosteroids, short-acting β2-agonist (SABA) and hospitalization. Medication use, asthma exacerbations, \\nand related costs in the follow-up period were also reported. \\nResults: 2,418 patients with severe asthma were included, with an average age of 56.15 years, male 55.62%. 93.51% of \\npatients used inhaled corticosteroid/long-acting β2 (ICS/LABA). 10.75% of patients used oral corticosteroids (OCS) (6.13%, \\n23.83% and 33.96% in controlled, sub-optimally controlled and uncontrolled group, respectively). For patients with OCS, \\nthe average duration of OCS was 82.73 days (53.35, 102.27 and 111.21 days in three groups, respectively). 10.67% of \\npatients experienced ≥ 1 exacerbation and 3.93% experienced ≥ 2 exacerbations (1.73%,1.68% and 26.89% in three groups, \\nrespectively). The average frequency of annual exacerbations was 0.21 (0.09, 0.26 and 1.31 in three groups, respectively). The \\naverage cost for per exacerbation was ¥1441.83 (¥293.69, ¥550.86 and ¥2366.86 in three groups respectively). The average \\nasthma-related annual cost was ¥2846.08, of which medication costs exceeded 90% (¥2105.70, ¥3559.35 and ¥8506.83 in \\nthree groups, respectively). \\nConclusion: This study shows that ICS/LABA is widely used in patients with severe asthma, and OCS is more used in patients \\nwith uncontrolled asthma. Worse asthma control is associated with more frequent and severe asthma attack and higher medical \\ncost, which reveals the necessity of effective management and treatment to improve the asthma control. \\nKey words: severe asthma, control level, treatment pattern, disease burden, real-world study\",\"PeriodicalId\":430023,\"journal\":{\"name\":\"Health Decision\",\"volume\":\"59 7\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health Decision\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54844/hd.2024.0011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Decision","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54844/hd.2024.0011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:评估中国成人重症哮喘患者的治疗模式和疾病负担:评估中国成人重症哮喘患者的治疗模式和疾病负担。研究方法:采用回顾性、观察性、队列研究和一年随访的方法:本研究是一项回顾性、观察性、队列研究,使用中国天津市的医疗报销数据库进行为期一年的随访,时间跨度为 2018 年至 2020 年。被诊断为哮喘的患者中,有≥2张中高剂量吸入式皮质类固醇(ICS)处方和额外的控制剂处方的患者被确定为中国重症哮喘人群的代表。根据患者使用全身皮质类固醇、短效β2-受体激动剂(SABA)和住院治疗的时间,将患者分为已控制、未达到最佳控制和未控制三类。此外,还报告了随访期间的用药情况、哮喘加重情况和相关费用。结果:共纳入 2418 名重症哮喘患者,平均年龄 56.15 岁,男性占 55.62%。93.51%的患者使用吸入式皮质类固醇/长效β2(ICS/LABA)。10.75%的患者使用口服皮质类固醇(OCS)(控制组、次优控制组和未控制组分别为 6.13%、23.83% 和 33.96%)。在使用口服皮质类固醇的患者中,口服皮质类固醇的平均持续时间为 82.73 天(三组分别为 53.35 天、102.27 天和 111.21 天)。10.67%的患者病情加重≥1次,3.93%的患者病情加重≥2次(三组分别为 1.73%、1.68% 和 26.89%)。每年恶化的平均频率为 0.21(三组分别为 0.09、0.26 和 1.31)。每次病情加重的平均费用为 1441.83 日元(三组分别为 293.69 日元、550.86 日元和 2366.86 日元)。与哮喘相关的年平均费用为 2846.08 日元,其中药物费用超过 90%(三组分别为 2105.70 日元、3559.35 日元和 8506.83 日元)。结论本研究表明,ICS/LABA 被广泛用于重症哮喘患者,而 OCS 则更多地用于未得到控制的哮喘患者。较差的哮喘控制与更频繁、更严重的哮喘发作和更高的医疗费用相关,这揭示了有效管理和治疗以改善哮喘控制的必要性。关键词:重症哮喘、控制水平、治疗模式、疾病负担、真实世界研究
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Disease burden and treatment patterns in adult patients with severe asthma: A real-world study based on claims data from China
Objective: To assess the treatment pattern and disease burden in adults with severe asthma in China. Methods: This retrospective, observational, cohort study with one-year follow-up was conducted using a healthcare claims database spanning 2018 through 2020, from Tianjin, China. Patients diagnosed with asthma, who had ≥2 prescriptions of medium-to-high dose of inhaled corticosteroids (ICS) along with additional controllers, were identified to represent severe asthma population in China. Patients were categorized as controlled, sub-optimally controlled , and uncontrolled by the times of burst systemic corticosteroids, short-acting β2-agonist (SABA) and hospitalization. Medication use, asthma exacerbations, and related costs in the follow-up period were also reported. Results: 2,418 patients with severe asthma were included, with an average age of 56.15 years, male 55.62%. 93.51% of patients used inhaled corticosteroid/long-acting β2 (ICS/LABA). 10.75% of patients used oral corticosteroids (OCS) (6.13%, 23.83% and 33.96% in controlled, sub-optimally controlled and uncontrolled group, respectively). For patients with OCS, the average duration of OCS was 82.73 days (53.35, 102.27 and 111.21 days in three groups, respectively). 10.67% of patients experienced ≥ 1 exacerbation and 3.93% experienced ≥ 2 exacerbations (1.73%,1.68% and 26.89% in three groups, respectively). The average frequency of annual exacerbations was 0.21 (0.09, 0.26 and 1.31 in three groups, respectively). The average cost for per exacerbation was ¥1441.83 (¥293.69, ¥550.86 and ¥2366.86 in three groups respectively). The average asthma-related annual cost was ¥2846.08, of which medication costs exceeded 90% (¥2105.70, ¥3559.35 and ¥8506.83 in three groups, respectively). Conclusion: This study shows that ICS/LABA is widely used in patients with severe asthma, and OCS is more used in patients with uncontrolled asthma. Worse asthma control is associated with more frequent and severe asthma attack and higher medical cost, which reveals the necessity of effective management and treatment to improve the asthma control. Key words: severe asthma, control level, treatment pattern, disease burden, real-world study
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信